Butterfly Network Inc (BFLY): Top Medical AI Stock to Buy

Why It Matters

The approval expands access to rapid prenatal imaging, a critical need in underserved areas, while the strong revenue growth underscores BFLY’s ability to capture a fast‑growing market.

Key Takeaways

• FDA cleared AI handheld ultrasound for gestational age estimation
• Tool delivers results in under two minutes, aiding emergencies
• Revenue rose 41% YoY to $31.5 million, beating estimates
• Handheld ultrasound market projected to hit $1.13 billion by 2034

Pulse Analysis

The FDA’s clearance of Butterfly Network’s AI‑driven handheld ultrasound marks a pivotal shift in obstetric care. By delivering gestational age estimates in under two minutes, the device addresses a long‑standing bottleneck in prenatal diagnostics, especially in emergency rooms and remote clinics where traditional imaging is scarce. The underlying model, trained on millions of scans from varied populations, promises consistent accuracy across demographic lines, potentially reducing disparities in maternal health outcomes.

Beyond the clinical advantage, the approval unlocks a sizable market opportunity. Industry analysts project the global handheld ultrasound sector to surge from roughly $397 million today to $1.13 billion by 2034, driven by demand for point‑of‑care imaging and the proliferation of mobile health platforms. Butterfly’s iQ+ and iQ3 devices, already integrated with a smartphone interface, give it a competitive edge in speed-to-market and user adoption, positioning the firm to capture a meaningful share of this growth trajectory.

Financially, Butterfly demonstrated robust momentum in Q4 2025, posting $31.5 million in revenue—a 41% YoY jump—and narrowing its adjusted loss per share to $0.02. With $150.5 million in cash, the company is well‑capitalized to scale production, invest in further AI enhancements, and expand into international markets where prenatal imaging gaps are even wider. While the stock’s recent 90% rally reflects optimism, investors should weigh the upside against broader AI‑stock volatility and emerging competitors in the portable imaging space.